Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
Holding DCTH?
Track your performance easily
DCTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $11.75
Previous Close$9.05
Volume161.69K
Average Volume (3M)269.42K
Market Cap
$260.40M
Enterprise Value$239.07M
Total Cash (Recent Filing)$19.91M
Total Debt (Recent Filing)$5.58M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 12, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding27,999,522
10 Day Avg. Volume254,885
30 Day Avg. Volume269,417
Standard Deviation0.22
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)60.33
Price to Sales (P/S)22.11
Price to Cash Flow (P/CF)-14.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.13
Enterprise Value/Gross Profit167.18
Enterprise Value/Ebitda-4.28
Forecast
1Y Price Target
$21.00Price Target Upside125.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Delcath Systems News
PremiumCompany Announcements
Delcath Systems Reveals Encouraging Uveal Melanoma Study Results
PremiumPre-Earnings
Is DCTH a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Analyst SentimentAnalysts are optimistic about Delcath Systems, with a 'Buy' recommendation and a $16 price target based on the strong sales potential and market opportunity for Hepzato.
Growth And AdoptionWith over 20 sites interested in Hepzato and expectations of more sites offering the treatment, there's a clear trajectory for increased usage and market penetration.
Product Approval And Market PotentialThe FDA approval of the Hepzato Kit for metastatic ocular melanoma marks a significant step forward, potentially disrupting the market with a new treatment option.
Bears Say
Commercial Roll-out ImpactThe REMS program may initially limit the number of treatment sites able to offer Hepzato, affecting the speed of its commercial roll-out.
Operational HurdlesThe REMS Program requires extensive training and proctoring, which may initially limit the number of sites able to perform commercial cases immediately after launch.
Regulatory ChallengesThe REMS program may initially limit the number of sites able to perform commercial cases immediately after launch.
---
Ownership Overview
44.23% Insiders
4.35% Mutual Funds
33.40% Other Institutional Investors
18.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $2.25 and its highest was $11.74 in the past 12 months.
What is Delcath Systems’s market cap?
Currently, no data Available
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 05, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.118.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -$0.22.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 27,999,521 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -4.928%.
Which hedge fund is a major shareholder of Delcath Systems?
Among the largest hedge funds holding Delcath Systems’s share is Deerfield Management Company, LP. It holds Delcath Systems’s shares valued at N/A.
---
Delcath Systems Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (125.81% Upside)
$21.00 (125.81% Upside)
Hedge Fund Trend
Decreased
By 486.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.68%
12-Months-Change
Fundamentals
Return on Equity
-2852.05%
Trailing 12-Months
Asset Growth
61.11%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.
---
DCTH Earnings Call
Q2 2024
0:00 / 0:00
---
DCTH Stock 12 Month Forecast
Average Price Target
$21.00
▲(125.81% Upside)
Technical Analysis
Best Analysts Covering DCTH
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+28.96%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +28.96% per trade.
---